A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Sponsor
AB Science
Study ID
NCT01045577
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Masitinib — DRUG
    6 mg/kg/day
  • Masitinib — DRUG
    3 mg/kg/day
  • Placebo — DRUG
    Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)

Study Details

A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis

Key Dates

Start date
Sep 30, 2005
Status verified
Dec 2018
Primary completion
Jan 31, 2006
Completion
Feb 29, 2008

Study Design

Enrollment
25 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Masitinib (AB1010)
    Masitinib (AB1010)
  • Placebo Comparator: Placebo mactching masitinib
    Placebo matching masitinib

Primary Outcome Measure

Change from baseline in BSA after 12 weeks of treatment [ Time Frame: 12 weeks ]

Related Studies